All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
Bookmark this article
The MPN Hub were pleased to speak to Jacqueline S. Garcia, Dana-Farber Cancer Institute, Boston, US, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. We asked: Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
Jacqueline S. Garcia comprehensively discusses a phase II clinical trial that added the BH3 mimetic, navitoclax, to ruxolitinib treatment in patients with myelofibrosis to increase patient response rate with this combination. She discusses the patient inclusion criteria, treatment regimen, safety, response rates, primary endpoints and overall outcome to this novel combination. She concludes by stating that this novel combination looks to be highly encouraging in producing clinically meaningful outcomes.
Can navitoclax plus ruxolitinib induce clinically relevant responses in patients with myelofibrosis?
Your opinion matters
0 votes - 29 days left ...
Related articles
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox